Aurinia Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
All right. welcome to the 41st Annual JPMorgan Healthcare Conference. My name is Matt Bannon, and I'm a banker here at JPM. I'm really excited to be setting the stage for our next presenting company, Aurinia Pharmaceuticals. And on behalf of Aurinia, we have CEO, Peter Greenleaf. So Peter, the stage is yours.
Thanks, Matt, and thanks to JPMorgan for having us here at the conference this year. Looking forward to the next 40 minutes or so between the presentation and the Q&A to update you all on our progress as a company as we enter the new year. And we've had some good news entering it, so I look forward to updating you on all fronts for the company.
Before I do, of course, I want to just point you to our forward-looking statements and as well for most -- our most recent filings with the FDA, to just point you to our site at aurinia.com and our Investors section there.
If you don't know who the organization is, a good place to start is we're a fully
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |